In the USA, VAP is the second most common hospital-acquired infection among pediatric intensive care unit (PICU) patients, is responsible for an increased length of stay and an attributable health-care cost estimated at over $30,000. VAP has also been associated with the emergence of antibiotic-resistant microorganisms.
With the NICU implementation of Steril-Aire UVC, the Women and Children’s Hospital of Buffalo has realized an $800,000/year reduction in direct costs and a $1.7 million/year reduction in 3rd party charges. VAP has a mortality rate estimated to be as high as 27.1%, the Steril-Aire solution is literally priceless.